| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.46 MB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
A dissertação que apresento encontra-se inserida na unidade curricular designada de “Estágio” do Mestrado Integrado de Ciências Farmacêuticas, da Faculdade de Ciências da Saúde da UBI. Desta dissertação constam três componentes: a primeira referente ao estágio em farmácia comunitária, a segunda ao estágio em farmácia hospitalar e a restante ao trabalho de pesquisa bibliográfica, uma revisão da literatura no âmbito dos Novos Anticoagulantes Orais e sobre o seu perfil de utilização e de efeitos adversos em Portugal, mas com recurso e não esquecendo a panorâmica de outros países.
O primeiro capítulo retrata a minha experiência e o meu primeiro contacto com a farmácia. Durante o período em que efetuei o estágio na Farmácia São João tive a oportunidade de conhecer melhor as necessidades da população e nesta situação em concreto da população da Covilhã. Aqui aprendi e aprimorei, igualmente, os conhecimentos e competências que adquiri na Universidade.
O segundo capítulo relata o conhecimento e capacidades técnicas que adquiri na passagem pelos Serviços Farmacêuticos do CHCB.
O capítulo que segue, refere o trabalho de investigação desenvolvido na área das novas terapias anticoagulantes orais. Nos últimos 60 anos, os antagonistas da vitamina K eram os únicos anticoagulantes orais disponíveis quer para a prevenção como para o tratamento das complicações tromboembólicas associadas à fibrilhação auricular e ao tromboembolismo venoso. As doenças do sistema circulatório são das patologias mais frequentes e com mais riscos associados em Portugal e no mundo. Os novos fármacos apresentam um perfil farmacocinético mais favorável e dispensam a monitorização de rotina. Estes estudos concluíram que os novos fármacos como o, dabigatrano, rivaroxabano e apixabano, são pelo menos tão eficazes e seguros como os antagonistas da vitamina K na prevenção dos eventos trombóticos e originam menos hemorragias e uma menor necessidade de monitorização. Apesar do benefício que trazem, é correto afirmar que também comportam uma despesa enorme para o SNS e talvez insuportável para certos serviços de saúde.
The dissertation that I present is included in the curricular unit called "Internship" of the Integrated Master of Pharmaceutical Sciences, in Faculty of Health Sciences, UBI. This dissertation consists in three components: the first is a review of the practice in community pharmacy, the second refers to the internship taht I did in hospital pharmacy and the ongoing work of bibliographical research, a review of the literature in the scope of the New Anticoagulants and its profile of use and adverse effects in Portugal, but with recourse and not forgetting the panorama of other countries. The first chapter portrays my experience and my first contact with a pharmacy. During the period in which the internship at the São João Pharmacy was held the opportunity to improve the current population situation and the situation in this case of Covilhã community. Here I also learned and improved the knowledge and skills that I acquired at the University. The second chapter reports the knowledge and technical capabilities that are acquired of the CHCB Pharmaceutical services. The following chapter refers to the research work developed in the area of new oral anticoagulant therapies. Over the past 60 years, vitamin K antagonists have been the only oral anticoagulants available for prevention as for the treatment of thromboembolic complications associated with atrial fibrillation and venous thromboembolism. Diseases of the circulatory system are the most frequent and with more risks associated in Portugal and in the world. New drugs have a more favorable pharmacokinetic pattern and don’t require routine monitoring. These studies have concluded that new drugs such as dabigatran, rivaroxaban, and apixaban are as good as vitamin K antagonists and origin less bleeding episodes. Despite the benefit, this therapy have a problem that is a huge expense to the our SNS and perhaps unbearable for some health services.
The dissertation that I present is included in the curricular unit called "Internship" of the Integrated Master of Pharmaceutical Sciences, in Faculty of Health Sciences, UBI. This dissertation consists in three components: the first is a review of the practice in community pharmacy, the second refers to the internship taht I did in hospital pharmacy and the ongoing work of bibliographical research, a review of the literature in the scope of the New Anticoagulants and its profile of use and adverse effects in Portugal, but with recourse and not forgetting the panorama of other countries. The first chapter portrays my experience and my first contact with a pharmacy. During the period in which the internship at the São João Pharmacy was held the opportunity to improve the current population situation and the situation in this case of Covilhã community. Here I also learned and improved the knowledge and skills that I acquired at the University. The second chapter reports the knowledge and technical capabilities that are acquired of the CHCB Pharmaceutical services. The following chapter refers to the research work developed in the area of new oral anticoagulant therapies. Over the past 60 years, vitamin K antagonists have been the only oral anticoagulants available for prevention as for the treatment of thromboembolic complications associated with atrial fibrillation and venous thromboembolism. Diseases of the circulatory system are the most frequent and with more risks associated in Portugal and in the world. New drugs have a more favorable pharmacokinetic pattern and don’t require routine monitoring. These studies have concluded that new drugs such as dabigatran, rivaroxaban, and apixaban are as good as vitamin K antagonists and origin less bleeding episodes. Despite the benefit, this therapy have a problem that is a huge expense to the our SNS and perhaps unbearable for some health services.
Description
Keywords
Antagonistas da Vitamina K Antídotos. Farmácia Comunitária Farmácia Hospitalar Novos Anticoagulantes Orais Riscos